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An optimised protocol has been developed for the coupling of dihydroartemisinin benzoate with a range of aromatic
allylsilanes to provide a number of new C-10 deoxo derivatives (11a–11g) in yields ranging from 70 to 94%. These
compounds were up to ten times more potent than artemisinin in in vitro tests against the chloroquine resistant K1
strain of Plasmodium falciparum. Ferrous mediated degradation of these analogues produces as the main product, a
dicarbonyl formate 12, which is not seen when the same reaction is carried out with artemisinin or artemether. This
ﬁnding may indicate that analogues in this class have a subtly diﬀerent “antimalarial” mechanism of action.
Introduction
Malaria has a devastating eﬀect throughout the tropics. There
are approximately 300 to 500 million clinical cases each year
resulting in 1.5 to 2.7 million deaths. Nearly all fatal cases are
caused by Plasmodium falciparum.1 The problem is com-
pounded by the spread of drug resistant strains of the parasite.
As a result traditional alkaloid drugs such as chloroquine 1 and
quinine are now largely ineﬀective.
In 1979 it was shown that artemisinin (Qinghaosu) 2, a
sesquiterpene 1,2,4-trioxane isolated from the Chinese
medicinal herb qinghao (Artemisia annua L.), was an eﬀec-
tive antimalarial against chloroquine-resistant strains of
Plasmodium falciparum.2 Artemisinin has been very impressive
in preliminary pharmacological testing; however its poor solu-
bility in both oil and water and hydrolytic instability of the
lactone function has led scientists to prepare a series of semi-
synthetic ﬁrst generation analogues such as artemether (3a,
R = –CH3) and arteether (3b, R = –CH2CH3).3 Both of these
derivatives are readily prepared from dihydroartemisinin
(DHA, 3c), which in turn is produced by borohydride mediated
reduction of the D-ring lactone of 2.4 Although 3a and 3b are
potent antimalarials, poor bioavailability and rapid clearance
are observed with these derivatives both in man and in animal
models.5 This phenomenon is associated with the inherent
chemical and metabolic instability of the acetal functionality.
One of the main routes of metabolism of artemether in the rat
model involves P450 mediated hydroxylation of the C-10
methyl ether function to an unstable hemiacetal that hydrolyses
to dihydroartemisinin.6 This phase 1 metabolite then undergoes
Phase II glucuronidation and is excreted as dihydroartemisinin
β-glucuronide.7
The increased stability of non acetal-type analogues (e.g.4) of
artemisinin has recently been reported. C-10-Deoxoartemis-
inins have been shown to be 15–22 times more stable than
acetal-type analogues in simulated stomach acid.8 Such favour-
able ﬁndings have led several groups to develop synthetic and
semisynthetic approaches to C-10-deoxoartemisinin derivatives.
Early syntheses tended to be lengthy, using artemisinic acid as
starting material.9 Pu and Ziﬀer 10 successfully used DHA with
allyltrimethylsilane in the presence of boron triﬂuoride–diethyl
ether to synthesise a wide range of these compounds and
have more recently shown that dihydroartemisinin acetate can
be employed as starting material using silyl enol ethers in the
presence of titanium tetrachloride.11 Posner and coworkers
have reported a two-step conversion of DHA, via an inter-
mediate 10-ﬂuoro derivative, into a series of aromatic and
heterocyclic deoxoartemisinin derivatives.12–13 Wang et al., via
the acid-catalysed reaction of dihydroartemisinin acetate with
2-naphthol, produced two 10-(2-hydroxy-1-naphthyl)deoxo-
artemisinins.14 Previously, we have reported on the synthesis of
a range of potent C-10-deoxo carba ether and ester derivatives,
some of which were more than ﬁfteen times more potent than
the parent drug artemisinin.15 In this paper, we report on an
optimised approach to C-10 carba analogues which is based
on the Lewis acid catalysed reaction of a range of allylsilanes
with an anomerically activated C-10 benzoate of dihydro-
artemisinin. We also report on the potent activity of these new
derivatives, which, based on biomimetic Fe() chemistry, may
be diﬀerent from the parent drug artemisinin.16
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Results and discussion
A key intermediate for the preparation of a range of carba
analogues of artemisinin, including parasite targeted amine
analogues,17 water soluble sugar analogues,18 ﬂuorinated benzyl
ethers 15 and antitumour dimers,19 is C-10-allyldeoxoartemisinin
4a. The original synthesis of 4a involves Lewis acid mediated
(BF3Et2O) reaction of DHA with allyltrimethylsilane as
carbon nucleophile. In this reaction, it is proposed that the
product is derived by axial attack of allyltrimethylsilane on the
intermediate oxonium ion. (Scheme 1).
The drawback in the procedure is the harsh nature of the
Lewis acid, which results in the generation of substantial
amounts of the dehydration product anhydroartemisinin 4b
(AHA). This makes puriﬁcation of the desired material
extremely diﬃcult on a large scale since 4a and 4b have very
similar Rfs on silica gel. We reasoned that a milder Lewis acid
and a better anomeric leaving group would improve the yield
of 4a. In considering the choice of Lewis acid, we also noted
that hard Lewis acids such as BF3Et2O, have the capacity to
rearrange target C-10 carba derivatives whereas weaker Lewis
acids such as zinc chloride do not. Indeed, in several large-scale
runs using BF3Et2O as Lewis acid, several unwanted products
were observed including the deoxygenated trioxane by-product
shown in Scheme 2.20 The mechanism for the formation
of this product is believed to involve an acid-catalysed C–O
migration. With these observations in mind, zinc chloride was
chosen as a mild Lewis acid for the coupling reaction with
C-10α-benzoate 5.
The benzoate 5 was prepared in high yield by treatment of
DHA with benzoyl chloride in pyridine. NMR studies on the
white crystalline solid indicated (α) stereochemistry with
respect to the C–O linkage at C-10 (C-10 H appears as a doub-
let with a J9–10 value of 9.9 Hz indicating a dihedral angle
of about 180 between itself and C-9 H). After several runs
using diﬀerent temperatures and solvents, optimum conditions
were found where the product could be obtained in high yields
with only minor quantities of the by-product, 4b. Thus, reac-
tion of the benzoate with allyltrimethylsilane (5 equivalents)
in the presence of ZnCl2 catalyst (1.2 equivalents) at 0 C
for 4 h gave the desired product, 4a, in 90% yield (Scheme 3).
This result suggests that the leaving group and Lewis acid
are perfectly tuned for eﬀecting controlled oxonium generation
and subsequent reaction with allylsilanes as nucleophiles. Given
the dramatic improvement in yield, we reasoned that this
approach should be readily applicable to other reactive allyl-
silanes bearing lipophilic, ﬂuorinated aromatic rings, substitu-
ents previously shown to improve the biological activity of
peroxide based antimalarials.21–22 Two approaches were
Scheme 1
considered for the preparation of requisite allylsilanes; (i) the
cerium mediated conversion of esters to allylsilanes 23 and (ii)
Ni(acac)2 cross coupling of silylenol ethers with trimethylsilyl-
methylmagnesium chloride.24
Preparation of allylsilanes
Cerium mediated conversion of esters to allylsilanes.23 Recent
interest has focused on the use of carboxylic acid derivatives as
functional precursors for allylsilanes.23,25,26 The transformation
includes twofold addition of a trimethylsilylmetal to the ester
yielding the bis(β-silyl) alcohol, which on deoxysilylation leads
to the allylsilane 7 (Scheme 4).
The reaction has been successful, although low yielding, for
esters of unbranched carboxylic acids using trimethylsilyl-
methylmagnesium chloride.25 The reaction fails completely
when using esters of α-branched carboxylic acids 25 where the
α-silyl-ketone intermediate resists further addition of Grignard
Scheme 2
Scheme 3
Scheme 4
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in favour of kinetic enolization. Imamoto, however, has shown
that organocerium reagents are especially suited for additions
to readily enolized carbonyl systems.27 The reagent used in our
reaction was therefore a preparation of CeCl3 and trimethyl-
silylmethylmagnesium chloride. Unfortunately this procedure
proved very unreliable and frequently, very poor yields of target
allylsilanes were obtained (Table 1). The variation in yields
prompted us to investigate other methods for synthesising the
required allylsilanes.
Nickel-catalyzed cross-coupling of silyl enol ethers with Grignard
reagents 24
In this reaction a silyl enol ether is allowed to react with a
Grignard reagent in the presence of nickel acetylacetonate,
Ni(acac)2, as catalyst. This gives the cross-coupled product in
excellent yield. A range of silyl enol ethers were prepared from
commercially available acetophenone derivatives and the result-
ing enol ethers converted into target allylsilanes. Yields for the
synthesis of both silyl enol ethers and allylsilanes are recorded
in Table 2.
The yields for the silyl enol ethers ranged from 60 to 80%,
with NMR and accurate mass spectrometry establishing the
purity of the compounds. In most cases, good yields were
achieved for the synthesis of target allylsilanes with one notable
exception. No reaction was observed on trying to convert 9c to
the desired allylsilane 10c. A possible explanation is that the
large p-triﬂuoromethyl group is hindering insertion of the
catalytically active nickel species into the styryl function of 9c.
Table 1
Starting material Product Yield
6a (R = p-CF3) 7a (R = p-CF3) 20–67%
6b (R = m-F) 7b (R = m-F) 30–73%
Deoxoartemisinin derivatives
With a range of allylsilanes to hand, we then applied our opti-
mized coupling conditions. C-10 benzoate 5 was allowed to
react with a given allylsilane (7a, 7b and 10a, b, d, e) in the
presence of zinc chloride at 0 C for approximately 4 hours.
After extraction into DCM and washing with 5% aqueous citric
acid solution, column chromatography furnished the desired
compounds as white foams in excellent yield and high purity. A
generalised reaction is shown in Scheme 5 and the results are
listed in Table 3.
The observed stereochemistry in analogues 11a–11g is (β) at
the C-10 carbon and this is in line with observations made by
Ziﬀer 10 using a mechanism proposed by Kishi 28, where the
nucleophile attacks 5 in an axial manner (Scheme 1). The high
yields obtained for target carba analogues compares favourably
with other approaches to this type of system. The presence of
the C–C linkage should ensure that these compounds have
greater metabolic stability than the ﬁrst generation derivatives
artemether and arteether.
Three of the new compounds were tested in vitro versus the
highly chloroquine resistant K1 strain of Plasmodium falci-
parum (Table 4). Compounds 11f and 11g were 10 times more
potent than artemisinin and 3 fold more potent than artem-
ether. Table 4 also includes data for chloroquine and allyl-
deoxoartemisinin 4a. The data clearly demonstrate that the
incorporation of lipophilic ﬂuorinated aryl rings is beneﬁcial to
antimalarial activity since 11d, 11f and 11g are more active as
antimalarials than 4a.
Scheme 5
Table 2 Ni(acac)2 mediated synthesis of allylsilanes
Starting material Silyl enol ether Yield Allylsilane Yield
8a, R =–H 9a, R = –H,  10a, R = –H 42%
8b, R = –m-CF3 9b, R = –m-CF3 75% 10b, R = –m-CF3 70%
8c, R–o-CF3 9c, R–o-CF3 78% 10c, R–o-CF3 No reaction
8d, R = p-F 9d, R = p-F 78% 10d, R = p-F 81%
8e, R = o-F 9e, R = o-F 80% 10e, R = o-F 50%
8f, R = p-OMe 9f, R = p-OMe 60% 10f, R = p-MeO- 40%
2684 J. Chem. Soc., Perkin Trans. 1, 2001, 2682–2689
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The generally accepted mechanism of action of peroxide
antimalarials involves the interaction of the peroxide-
containing drug with haem, a haemoglobin degradation
by-product, derived from proteolysis of haemoglobin.29
This interaction is believed to result in the formation of a
range of potentially toxic oxygen and carbon-centred radicals.
In order to gain deeper mechanistic insight into the “actual”
radical intermediates or cytotoxic end-products generated,
several workers have employed biomimetic Fe() mediated
decompositions to simulate events in the ferrous rich parasite
food vacuole. Surprisingly, ferrous mediated degradation of 11a
Table 3 Yields of C-10 deoxo analogues from allylsilanes
Allylsilane C-10-deoxoartemisinin Yield
10a 11a, Ar = Ph 91%
10b 11b, Ar = m-CF3-Ph 94%
10d 11d, Ar = p-F-Ph 86%
10e 11e, Ar = o-F-Ph 70%
7a 11f, Ar = p-CF3 81%
7b 11g, Ar = m-F-Ph 90%
Table 4 In vitro antimalarial activity of new analogues versus K1
Plasmodium falciparum
Analogue IC50 (nM) SD± a
Artemisinin (2) 17.1 4.2
Artemether (3a) 9.2 2.1
11d 3.9 0.8
11f 1.8 0.3
11g 2.5 0.8
4a 7.2 1.2
a SD± = standard deviation.
provided as the main product, the formate 12 in 60% yield.30
This type of product is not seen following identical degradation
of artemisinin or the ﬁrst generation compounds artemether or
arteether (Scheme 6, A).
Intraparasitic release of dicarbonyl formate 12, could in
theory be responsible for some of the antimalarial activity of
these analogues. Indeed in an earlier study on simpliﬁed C-3-
aryl trioxanes 13a and 13b, Posner and co-workers demon-
strated that C-12-β-orientated simpliﬁed trioxane 13a degrades
to a dicarbonyl function in a similar manner to that observed in
this study.31 It was proposed that intraparasitic release of this
potentially cross-linking dicarbonyl, could be responsible, in
part, for the high activity of these analogues. Interestingly, from
the mechanistic work of Posner and co-workers, the pathway of
ferrous mediated degradation of the trioxane was governed by
stereochemistry at the C-12 position, since in contrast to 13a,
C-12-α-orientated trioxane 13b generated products analogous
to those seen with artemether and artemisinin (Scheme 6, B).
The explanation as to why stereochemistry at the C-12 position
of simpliﬁed trioxanes and simply changing carbon for oxygen
at the C-10 position of artemisinin or ether derivatives, drives
the ferrous mediated cascade toward these dicarbonyl products
remains to be clariﬁed.
In summary, we have now developed an optimised approach
to C-10-carba analogues which delivers the products in up to
94% yield from the easily prepared C-10 benzoate of dihydro-
artemisinin. Some of these analogues are more than ten times
more potent than artemisinin.
Experimental
General
1H and 13C NMR spectra were recorded on Bruker AC200 and
Varian Gemini 300 spectrometers. Mass spectra were recorded
Scheme 6
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on VG analytical 7070E and Fisons TRIO 1000 spectrometers
using electron ionisation (EI) and chemical ionisation (CI).
Infrared spectra were recorded on a Perkin Elmer 1320 and
Perkin Elmer FTIR Paragon 1000 spectrometers in the range of
4000–600 cm1. Analytical TLC was performed on aluminium-
backed Merck silica gel 60 F254 plates. All liquid chromato-
graphy separations were performed using Merck Kieselgel
60 silica. Anhydrous DCM, DCE, diethyl ether, THF were
purchased in sure-seal bottles from the Aldrich Chemical
Company, and used as received. Acetonitrile was distilled from
calcium hydride under nitrogen.
General procedure 1: synthesis of silyl enol ethers
To a solution of ketone starting material (1.0 eq.) in anhydrous
ether (2 mL mmol1 of ketone) at 0 C was added Et3N (1.1 eq.)
via a syringe. To this mixture, at 0 C, was slowly added
TMSOTf (1.1 eq.) via a gas tight syringe. The resulting mixture
was stirred at 0 C for 15 min, warmed to rt, and stirred for
2 hours. Two phases were separated and the ethereal layer was
concentrated under reduced pressure. The crude product was
puriﬁed via Kugelrohr distillation to yield silyl enol ether with
some starting material.
General procedure 2: synthesis of allylsilanes (Ni(acac)2
catalysed)
To a mixture of trimethylsilylmethylmagnesium chloride in
ether (12.5 eq.) and Ni(acac)2 (1.0 eq.) in anhydrous ether
(50 mL) was added silyl enol ether starting material (6.3 eq.) at
rt under a nitrogen atmosphere. The resulting black solution
was heated under reﬂux for 3–6 hours and monitored by TLC
(2% ethyl acetate in hexane). After hydrolysis with dilute hydro-
chloric acid, and extraction into DCM, the organic phase was
washed with sodium bicarbonate and brine, dried with MgSO4 
and concentrated under reduced pressure. The product was
puriﬁed by ﬂash column chromatography with hexane.
General procedure 3: synthesis of allylsilanes (CeCl3 method)
Powdered CeCl37H2O (5.4 eq.) was dried in a vacuum oven
(30 mmHg, 160 C) overnight. The cooled ﬂask was vented with
nitrogen and anhydrous THF was added. The suspension was
stirred at rt for 2 h before being cooled to 70 C. Trimethyl-
silylmethylmagnesium chloride (5 eq.) was added via a syringe
and the suspension left stirring for 1 h, at which time the ester
(1 eq.) was added over 2–3 min. Stirring was continued for 2 h
at 70 C upon which time the reaction was allowed to warm to
rt overnight. After quenching with hydrochloric acid (1 M), the
crude product was isolated by extraction into DCM, drying
over MgSO4 and solvent removal under reduced pressure. The
product was puriﬁed by ﬂash chromatography with hexane.
General procedure 4: synthesis of deoxoartemisinin derivatives
To a solution of allylsilane (4.8 eq.) in anhydrous DCE (5 mL)
was added ZnCl2 (1.2 eq.) and 4 Å molecular sieves under an
inert nitrogen atmosphere. The mixture was cooled to 0 C
before adding a solution of benzoate (1 eq. in DCE (5 mL)) and
leaving to stir at 0 C for 4 h. After quenching with 5% aq. citric
acid solution and separating the organic phase, the crude
product was extracted from the aqueous layer into ethyl acetate.
The combined organic extracts were washed with saturated
NaHCO3 and brine, dried over MgSO4 and the solvent removed
under reduced pressure. The product was puriﬁed by ﬂash
chromatography with hexane and ethyl acetate (10 : 1) as
eluent.
Dihydroartemisinin 10-benzoate 5
To a solution of DHA (5.0 g, 1.76 mol) in anhydrous DCM
(54 mL) under an inert nitrogen atmosphere was added
anhydrous pyridine (9 mL). The mixture was cooled to 0 C
before adding benzoyl chloride (3.17 mL 2.73 mol). After stir-
ring at 0 C for 15 min, the reaction mixture was allowed to
warm to rt and was left for 16 h. The reaction was quenched
with 7% aq. citric acid solution and the aqueous phase
extracted with ethyl acetate (3 × 100 mL). The combined
organic extracts were washed with 7% aq. citric acid solution
followed by saturated NaHCO3 and ﬁnally dried over MgSO4.
The crude mixture was recrystallised from diethyl ether and
hexane (1 : 1) at 0 C to yield white crystals (4.14 g, 61% yield).
νmax (Nujol mull)/cm
1 2927, 1737, 1492, 1453, 1113, 876; 1H
NMR (300 MHz, CDCl3) δ 8.14–8.11 (2H, m, Ar), 7.57 (1H, m,
Ar), 7.47–7.42 (2H, m, Ar), 6.02 (1H, d, J = 9.9 Hz, 10-H), 5.53
(1H, s, 12-H), 2.76 (1H, m, 9-H), 2.40 (1H, dt, J = 12.9, 4.0 Hz),
2.04 (1H, m), 1.94–1.20 (9H, m), 1.43 (3H, s, CH3 at C3), 0.98
(3H, d, J = 6.0 Hz, CH3), 0.93 (3H, J = 7.2 Hz, CH3); 13C NMR
(75 MHz, CDCl3) δ 165.45, 133.38, 130.21, 129.79, 128.39,
104.46, 92.60, 91.64, 80.19, 51.66, 45.34, 37.22, 36.23, 34.09,
31.94, 25.86, 24.52, 21.98, 20.13, 12.11; MS m/z (CI, NH3) 284.3
(35%), 267.3 (55), 249.2 (15), 238.3 (18), 221.2 (100), 207.2 (80),
162.2 (31), 149.1 (7), 105.1 (16); Found 406.22436. C22H32NO6
[M  NH4]
 requires 406.2296, found: C, 68.03; H, 7.25;
requires C, 68.02; H, 7.26%.
Trimethyl[2-(4-triﬂuoromethylphenyl)allyl]silane 7a
This was synthesised in accordance to general procedure 3
using 4-triﬂuoromethylbenzoic acid methyl ester (0.16 mL,
1.0 mmol). Puriﬁcation of the product resulted in a clear oil
(0.17 g, 67% yield). νmax (neat)/cm
1 3092.0, 1618.0, 1280.0,
1015.0, 846.0; 1H NMR (300 MHz, CDCl3) δ 7.57–7.48 (4H, m,
Ar), 5.18 (1H, d, J = 1.5 Hz), 4.96 (1H, d, J = 0.9 Hz), 2.02 (2H,
d, J = 1.2 Hz), 0.10 (9H, s); 13C NMR (75 MHz, CDCl3)
δ 148.03, 147.17, 130.61, 128.13, 127.64, 126.64 (1C, d, JC–F =
3.8 Hz), 113.53, 27.51, 0.00; MS m/z (EI) 243 (6.25%), 203
(7.11), 166 (32.57), 165 (19.14), 164 (6.07), 146 (5.89), 145
(9.43), 116 (9.43), 115 (14.71), 75 (7.50), 74 (8.21), 73 (100.00),
45 (12.71), 43 (11.00); Found 258.10512. C13H17SiF3 requires
258.10516.
[2-(3-Fluorophenyl)allyl]trimethylsilane 7b
This was synthesised in accordance to general procedure 3
using ethyl 3-ﬂuorobenzoate (0.15 mL, 1.0 mmol). Puriﬁcation
of the product resulted in a clear oil (0.15 g, 73% yield). νmax
(neat)/cm1 3090.0, 1611.0, 1265.0, 1159.0, 875.0, 851.0; 1H
NMR (300 MHz, CDCl3) δ 7.38–6.99 (4H, m, Ar), 5.24 (1H, d,
J = 1.5 Hz), 4.99 (1H, d, J = 1.2 Hz), 2.07 (2H, s), 0.00 (9H, s);
13C NMR (75 MHz, CDCl3) δ 162.86 (1C, d, JC–F = 243.5 Hz),
145.60, 145.28 (1C, d, JC–F = 7.1 Hz), 129.50 (1C, d, JC–F =
8.1 Hz), 122.02, 113.95 (1C, d, JC–F = 21.3 Hz), 113.25 (1C, d,
JC–F = 21.8 Hz), 111.00, 26.02, 1.53; MS m/z (EI) 193 (15.30%),
177 (6.09), 153 (18.66), 115 (24.00), 77 (7.65), 75 (6.25), 74
(7.65), 73 (100.00), 45 (8.46), 43 (6.90); Found 208.10834.
C12H17SiF requires 208.10835; found: C, 69.12; H, 8.25;
requires C, 69.18; H, 8.22%.
Trimethyl[1-(3-triﬂuoromethylphenyl)vinyloxy]silane 9b
This was synthesised in accordance to general procedure 1
using 3-(triﬂuoromethyl)acetophenone (1.83 mL, 12 mmol).
Puriﬁcation of the product by Kugelrohr distillation (70 C,
0.1 mmHg) resulted in a clear oil in 75% yield. 1H NMR
(300 MHz, CDCl3) δ 8.15–7.20 (4H, m, Ar), 4.91 (1H, d, J =
2.1 Hz), 4.49 (1H, d, J = 2.1 Hz), 0.00 (9H, s); MS m/z (EI) 245
(31.8%), 191 (16.64), 188 (12.92), 173 (100.00), 169 (13.48), 151
(15.73), 145 (66.57), 103 (17.98), 75 (30.34), 73 (12.50), 47
(10.39), 43 (14.40); Found 260.08330. C12H15F3OSi requires
260.08441.
Trimethyl[1-(2-triﬂuoromethylphenyl)vinyloxy]silane 9c
This was synthesised in accordance to general procedure 1
using 2-(triﬂuoromethyl)acetophenone (1.83 mL, 12 mmol).
2686 J. Chem. Soc., Perkin Trans. 1, 2001, 2682–2689
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Puriﬁcation of the product by Kugelrohr distillation (50–55 C,
0.1 mmHg) resulted in a clear oil (2.42 g, 78% yield). 1H NMR
(200 MHz, CDCl3) δ 7.63–7.19 (4H, m, Ar), 4.43 (1H, d, J =
1.6 Hz), 4.37 (1H, d, J = 1.6 Hz), 0.17 (9H, s); MS m/z (CI,
NH3) 245.0 (10%), 206.1 (50), 191.1 (15), 173.0 (60), 149.0 (24),
90.0 (100.0); Found 261.09329. C12H16OF3Si [M  H]
 requires
261.09225.
[1-(4-Fluorophenyl)vinyloxy]trimethylsilane 9d
This was synthesised in accordance to general procedure 1
using 4-ﬂuoroacetophenone (1.46 mL, 12 mmol). Puriﬁcation
of the product by Kugelrohr distillation (70–75 C, 0.1 mmHg)
resulted in a clear oil (1.71 g, 68% yield). 1H NMR (200 MHz,
CDCl3) δ 7.24–6.93 (4H, m, Ar), 4.81 (1H, d, J = 1.9 Hz), 4.37
(1H, d, J = 1.4 Hz), 0.24 (9H, s).
[1-(2-Fluorophenyl)vinyloxy]trimethylsilane 9e
This was synthesised in accordance to general procedure 1
using 2-ﬂuoroacetophenone (1.48 mL, 12 mmol). Puriﬁcation
of the product by Kugelrohr distillation (60–65 C, 0.1 mmHg)
resulted in a clear oil (2.01 g, 80% yield). 1H NMR (300 MHz,
CDCl3) δ 7.34–7.23 (1H, m, Ar), 7.03–6.75 (3H, m, Ar), 4.97
(1H, s), 4.63 (1H, d, J = 1.5 Hz), 0.20 (9H, s); 13C NMR
(75 MHz, CDCl3) δ 160.19 (1C, d, JC–F = 249.5 Hz), 150.50,
129.41 (1C, d, JC–F = 8.7 Hz), 128.88, 123.74 (1C, d, JC–F =
3.3 Hz), 115.98 (1C, d, JC–F = 23.5 Hz), 97.2 (1C, d, JC–F =
11.0 Hz), 30.83, 0.00; MS m/z (EI) 209 (36.44%), 195 (59.48),
173 (23.69), 77 (100.00), 73 (22.71); Found 210.08710.
C11H15OFSi requires 210.08762.
[1-(4-Methoxyphenyl)vinyloxy]trimethylsilane 9f
This was synthesised in accordance to general procedure 1
using 4-methoxyacetophenone (1.80 g, 12 mmol). Puriﬁcation
of the product by Kugelrohr distillation resulted in a orange oil
(1.66 g, 59% yield). 1H NMR (200 MHz, CDCl3) δ 7.95–6.82
(4H, m, Ar), 4.79 (1H, s), 4.32 (1H, s), 3.79 (3H, s), 0.25 (9H, s).
Trimethyl(2-phenylallyl)silane 10a
This was synthesised in accordance to general procedure 2
using 1-phenyl-1-(trimethylsiloxy)ethylene 9a (0.96 g, 5.0
mmol). Puriﬁcation of the product resulted in a clear oil (0.40 g,
42% yield). 1H NMR (300 MHz, CDCl3) δ 7.47–7.21 (5H, m,
Ar), 5.12 (1H, br s), 4.86 (1H, br s), 2.21 (2H, br s), 0.18 (9H, s);
13C NMR (75 MHz, CDCl3) δ 151.78, 128.17, 127.36, 126.41,
125.56, 110.10, 20.91, 0.00; found: C, 74.83; H, 9.41; requires C,
75.72; H, 9.53%.
Trimethyl[2-(3-triﬂuoromethylphenyl)allyl]silane 10b
This was synthesised in accordance to general procedure 2
using 9b (1.30 g, 5.0 mmol). Puriﬁcation of the product resulted
in a yellow liquid (0.70 g, 50% yield). νmax (neat)/cm
1 2960.0,
1620.0, 1281.0, 1128.0, 854.0; 1H NMR (300 MHz, CDCl3)
δ 8.54–7.27 (4H, m, Ar), 5.26 (1H, br s), 4.97 (1H, br s), 2.04
(2H, br s), 0.08 (9H, s); 13C NMR (75 MHz, CDCl3) δ 145.45,
143.61, 129.58, 128.61, 123.88, 123.11, 111.60, 26.04, 1.52;
MS m/z (EI) 243 (12.22%), 167 (5.05), 166 (47.41), 165 (20.19),
164 (5.56), 146 (9.58), 116 (11.81), 115 (17.78), 77 (11.85), 75
(5.00), 74 (7.41), 73 (100.00), 45 (11.62), 43 (7.87); Found
258.10487. C13H17F3Si requires 258.10516.
[2-(4-Fluorophenyl)allyl]trimethylsilane 10d
This was synthesised in accordance to general procedure 2
using 9d (1.05 g, 5.0 mmol). Puriﬁcation of the product resulted
in a yellow liquid (0.84 g, 81% yield). νmax (neat)/cm
1 2958.0,
1603.0, 1248.0, 1160.0, 838.0; 1H NMR (300 MHz, CDCl3)
δ 7.20–6.95 (2H, m, Ar), 7.20–6.95 (2H, m, Ar), 5.07 (1H, d, J =
1.5 Hz), 4.85 (1H, d, J = 0.9 Hz), 1.99 (2H, d, J = 1.2 Hz), 0.09
(9H, s); 13C NMR (75 MHz, CDCl3) δ 145.69, 127.95, 115.01,
114.73, 110.03, 26.33, 1.51; MS m/z (EI) 193 (5.51%), 153
(10.53), 115 (9.46), 75 (6.58), 74 (6.83), 73 (100.00), 45 (10.28);
Found 208.10854. C12H17FSi requires 208.10835; found: C,
69.33; H, 8.28; requires C, 69.18; H, 8.22%.
[2-(2-Fluorophenyl)allyl]trimethylsilane 10e
This was synthesised in accordance to general procedure 2
using 9e (1.05 g, 5.0 mmol). Puriﬁcation of the product resulted
in a yellow liquid (0.57 g, 50% yield). νmax (Nujol mull)/cm
1
2958.0, 1622.0, 1249.0, 1164.0, 880.0, 851.0; 1H NMR (300
MHz, CDCl3) δ 7.30–6.99 (4H, m, Ar), 5.02 (2H, br s), 2.05
(2H, br s), 0.11 (9H, s); 13C NMR (75 MHz, CDCl3) δ 142.68,
130.06, 128.65, 123.84, 115.88, 115.58, 113.79, 30.84, 27.43,
1.71; MS m/z (EI) 116 (9.85%), 115 (30.61), 77 (17.27), 74
(7.69), 73 (100.00), 45 (7.58); Found 208.10875. C12H17FSi
requires 208.10835; found: C, 68.46; H, 8.53; requires C, 69.18;
H, 8.22%.
[2-(4-Methoxyphenyl)allyl]trimethylsilane 10f
This was synthesised in accordance to general procedure 2
using 9f (1.11 g, 5.0 mmol). Puriﬁcation of the product resulted
in a orange liquid (0.41 g, 35% yield). νmax (Nujol mull)/cm
1
2957.0, 2850.0, 1608.0, 1248.0, 833.0; 1H NMR (300 MHz,
CDCl3) δ 7.44–7.41 (2H, m, Ar), 6.89–6.84 (2H, m), 5.28 (1H,
br s), 5.00 (1H, brs ), 3.82 (3H, s), 2.14 (2H, br s), 0.19 (9H, s);
13C NMR (75 MHz, CDCl3) δ 126.66, 113.63, 110.69, 55.30,
21.88, 0.05; MS m/z (EI) 205 (29.36%), 165 (100.00), 73 (37.77);
Found 220.12852. C13H20SiO requires 220.12834.
10-Allyldeoxoartemisinin 4a
This was synthesised in accordance to general procedure 4
using allyltrimethylsilane to give the product as a white solid
(90%, mp 77–79 C). The physical properties were identical to
those reported in ref. 8.
Anhydroartemisinin 4b
νmax (Nujol mull)/cm
1 2923.9, 2852.4, 1685.9, 1459.9, 1112.8,
880.2; 1H NMR (300 MHz, CDCl3) δ 6.19 (1H, s, 10-H), 5.42
(1H, s, 12-H), 2.41 (1H, dt, J = 13.9, 4.8 Hz), 2.04 (2H, m),
1.92 (1H, m), 1.74–1.36 (5H, m), 1.59 (3H, d, J = 1.2, CH3),
1.42 (3H, s, CH3 at C3), 1.14 (2H, m), 0.98 (3H, d, J = 6.0 Hz,
CH3); 
13C (75 MHz, CDCl3) δ 135.12, 108.11, 104.56, 89.74
(C10), 78.99, 51.50, 44.50, 37.50, 36.27, 34.14, 30.00, 25.89,
24.42, 20.25, 16.14.
10-(2-Phenylallyl)deoxoartemisinin 11a
This was synthesised in accordance to general procedure 4
using 10a (0.39 g, 2.0 mmol). Puriﬁcation of the product
resulted in a white glue (0.14 g, 91% yield). νmax (Nujol mull)/
cm1 2927.0, 1463.0, 1104.0, 895.0; 1H NMR (300 MHz,
CDCl3) δ 7.42–7.24 (5H, m, Ar), 5.36 (2H, br s), 5.27 (1H, d,
J = 1.4 Hz), 4.52 (1H, m, 10-H), 2.72–1.20 (17H, m), 0.97–0.92
(6H, m); 13C NMR (75 MHz, CDCl3) δ 128.26, 127.30, 126.47,
114.36, 102.80 (C12), 89.65 (C10), 71.70, 52.18, 44.24, 37.53,
36.69, 35.85, 34.49, 30.48, 25.75, 24.93, 20.09, 12.73; MS m/z
(EI) 338 (23.84%), 165 (20.93), 163 (44.19), 162 (100.00), 157
(24.61), 145 (28.49), 138 (21.12), 129 (24.42), 124 (21.32), 118
(36.82), 117 (31.20), 115 (35.85), 105 (43.02), 103 (31.98), 95
(32.56), 93 (22.29), 91 (58.14), 81 (32.56), 79 (23.06), 77 (31.78),
71 (23.84), 69 (36.24), 67 (23.84), 55 (51.94), 45 (88.37), 41
(35.66); Found 384.22957. C24H32O4 requires 384.23004; found:
C, 73.89; H, 8.31; requires C, 74.97; H, 8.39%.
10-[2-(3-Triﬂuoromethylphenyl)allyl]deoxoartemisinin 11b
This was synthesised in accordance to general procedure 4
using 10b (0.56 g, 2.2 mmol). Puriﬁcation of the product
J. Chem. Soc., Perkin Trans. 1, 2001, 2682–2689 2687
Pu
bl
ish
ed
 o
n 
19
 S
ep
te
m
be
r 2
00
1.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f L
iv
er
po
ol
 o
n 
19
/0
5/
20
14
 1
1:
46
:3
5.
 
View Article Online
resulted in a white glue (0.24 g, 94% yield). νmax (Nujol mull)/
cm1 2923.1, 1456.6, 1376.9, 1123.1, 880.7; 1H NMR (300
MHz, CDCl3) δ 7.71–7.42 (4H, m, Ar), 5.42 (1H, s), 5.37 (1H, s,
12-H), 5.35 (1H, s), 4.52 (1H, m, 10-H), 2.62 (1H, m, 9-H), 2.28
(1H, dt, J = 13.9, 4.0 Hz), 2.06–1.20 (12H, m), 1.25 (3H, s, CH3
at C3), 0.98 (3H, d, J = 5.7 Hz, CH3), 0.96 (3H, d, J = 7.8 Hz,
CH3); 
13C NMR (75 MHz, CDCl3) δ 145.02, 142.38, 129.74,
128.72, 123.99, 123.35, 116.03, 102.79 (C12), 89.72 (C10),
81.02, 71.42, 52.10, 44.11, 37.54, 36.64, 35.88, 34.44, 30.48,
25.67, 24.92, 24.79, 20.06, 12.59; MS m/z (EI) 163 (25.00%), 162
(53.19), 124 (23.01), 109 (20.74), 95 (28.46), 93 (23.54), 81
(27.79), 79 (21.68), 71 (20.61), 69 (31.38), 67 (24.20), 55 (59.04),
43 (100.00), 41 (36.17); Found 452.21724. C25H31O4F3 requires
452.21744.
10-[2-(4-Fluorophenyl)allyl]deoxoartemisinin 11d
This was synthesised in accordance to general procedure 4
using 10d (0.66 g, 3.2 mmol). Puriﬁcation of the product
resulted in a clear glue (0.26 g, 86% yield). νmax (Nujol mull)/
cm1 2922.7, 1455.9, 1375.8, 1125.9, 879.8; 1H NMR (300
MHz, CDCl3) δ 7.44–6.96 (4H, m, Ar), 5.34 (1H, s, 12-H),
5.30 (1H, s), 5.25 (1H, d, J = 1.2 Hz), 4.50 (1H, m, 10-H),
2.60 (1H, m, 9-H), 2.28 (1H, dt, J = 13.8, 3.7 Hz), 2.01–1.19
(12H, m), 1.26 (3H, s, CH3 at C3), 0.96 (3H, d, J = 6.1 Hz, CH3),
0.92 (3H, d, J = 7.6 Hz, CH3); 13C NMR (75 MHz, CDCl3)
δ 145.09, 137.56, 128.04 (1C, d, JC–F = 8.2 Hz), 115.18, 114.90,
114.40, 102.80 (C12), 89.72 (C10), 81.04, 71.50, 52.13, 44.16,
37.54, 36.67, 36.12, 34.46, 30.48, 25.74, 24.92, 24.79, 20.07,
12.65; MS m/z (CI, NH3) 373.2 (9%), 357.2 (100), 343.2 (19),
267.2 (8), 221.2 (9), 162.1 (7); Found 420.25622. C24H35NO4F
[M  NH4]
 requires 420.25501.
10-[2-(2-Fluorophenyl)allyl]deoxoartemisinin 11e
This was synthesised in accordance to general procedure 4
using 10e (0.46 g, 2.2 mmol). Puriﬁcation of the product
resulted in a colourless glue (0.14 g, 70% yield). νmax (Nujol
mull)/cm1 2923.4, 1448.2, 1375.4, 1092.9, 879.7; 1H NMR (300
MHz, CDCl3) δ 7.37–6.98 (4H, m, Ar), 5.40 (1H, s), 5.33 (1H, s,
12-H), 5.24 (1H, s), 4.40 (1H, m, 10-H), 2.61 (1H, m, 9-H), 2.29
(1H, dt, J = 12.8, 3.9 Hz), 2.01–1.17 (12H, m), 1.28 (3H, s, CH3
at C3), 0.96 (3H, d, J = 6.0 Hz, CH3), 0.88 (3H, d, J = 7.5 Hz,
CH3); 
13C NMR (75 MHz, CDCl3) δ 158.31, 143.06, 130.83,
128.81 (1C, d, J = 8.2 Hz), 124.09, 117.61, 115.56 (1C, d,
J = 23.0 Hz), 102.88 (C12), 89.51 (C10), 81.06, 72.09, 52.23,
44.29, 37.53, 36.70, 34.49, 30.37, 25.81, 24.88, 24.79, 20.12,
12.68; MS m/z (EI) 312 (21.94%), 175 (38.27), 163 (42.18), 162
(44.22), 161 (39.29), 149 (23.30), 147 (20.75), 135 (39.63), 133
(29.08), 123 (40.65), 121 (35.37), 115 (22.62), 109 (78.23), 107
(28.06), 101 (21.09), 95 (43.54), 93 (31.12), 91 (20.58), 81
(39.46), 79 (27.89), 71 (27.72), 69 (40.48), 67 (33.33), 55 (67.35),
43 (100.00), 41 (37.93); Found 402.22001. C24H31FO4 requires
402.22064.
10-[2-(4-Triﬂuoromethylphenyl)allyl]deoxoartemisinin 11f
This was synthesised in accordance to general procedure 4
using 7a (0.08 g, 0.3 mmol). Puriﬁcation of the product resulted
in a white glue (0.04 g, 81% yield). νmax (Nujol mull)/cm
1
2923.5, 1456.5, 1376.1, 1127.4, 879.9; 1H NMR (300 MHz,
CDCl3) δ 7.59–7.50 (4H, m, Ar), 5.42 (1H, s), 5.37 (1H, s,
12-H), 5.33 (1H, s), 4.52 (1H, m, 10-H), 2.64 (1H, m, 9-H), 2.31
(1H, m), 2.09–1.05 (12H, m), 1.21 (3H, s, CH3 at C3), 0.96 (3H,
d, J = 6.3 Hz, CH3), 0.94 (3H, d, J = 7.8 Hz, CH3); 13C NMR
(75 MHz, CDCl3) δ 145.12, 135.12, 126.80, 125.26, 116.30,
102.73 (C12), 89.83 (C10), 81.01, 71.19, 52.05, 44.06, 37.54,
36.27, 35.96, 34.42, 30.49, 25.61, 24.91, 24.80, 20.03, 12.57; MS
m/z (EI) 225 (20.00%), 163 (37.31), 162 (66.92), 159 (27.12), 151
(27.31), 124 (23.46), 123 (25.77), 121 (21.92), 109 (27.69), 107
(25.58), 95 (24.62), 81 (37.88), 79 (26.15), 71 (24.62), 69
(38.08), 55 (64.62), 43 (100.00), 41 (35.38); Found 452.21724.
C25H31F3O4 requires 452.21747.
10-[2-(3-Fluorophenyl)allyl]deoxoartemisinin 11g
This was synthesised in accordance to general procedure 4
using 7b (0.28 g, 1.3 mmol). Puriﬁcation of the product resulted
in a white glue (0.14 g, 90% yield). νmax (Nujol mull)/cm
1
2956.0, 1462.0, 1377.0, 1124.0, 872.0; 1H NMR (300 MHz,
CDCl3) δ 7.31–6.92 (4H, m, Ar), 5.38 (1H, d, J = 1.0 Hz), 5.34
(1H, s, 12-H), 5.31 (1H, d, J = 1.1 Hz), 4.52 (1H, m, 10-H), 2.62
(1H, m, 9-H), 2.27 (1H, dt, J = 13.7, 3.8 Hz), 2.02–1.18 (12H,
m), 1.27 (3H, s, CH3 at C3), 0.96 (3H, d, J = 7.6 Hz, CH3), 0.93
(3H, d, J = 7.7 Hz, CH3); 13C NMR (75 MHz, CDCl3) δ 162.95
(1C, d, JC–F = 244.1 Hz), 145.02, 143.97 (1C, d, JC–F = 7.1 Hz),
129.66 (1C, d, JC–F = 8.3 Hz), 122.10, 115.35, 114.07 (1C, d,
JC–F = 21.3 Hz), 113.45 (1C, d, JC–F = 21.8 Hz), 102.80 (C12), 89.75
(C10), 81.03, 71.42, 52.11, 44.13, 37.54, 36.68, 35.88, 34.45, 30.48,
25.71, 24.93, 24.80, 20.06, 12.61; MS m/z (EI) 175 (20.98%), 165
(26.57), 163 (35.31), 162 (54.55), 161 (21.85), 147 (21.50), 138
(30.42), 135 (21.50), 133 (22.20), 124 (26.75), 123 (22.20), 109
(41.08), 95 (21.85), 81 (28.50), 79 (22.38), 69 (24.83), 67 (22.90), 55
(60.14), 43 (100.00), 41 (37.41); Found 402.22040. C24H31O4F
requires 402.22064; found: C, 71.14; H, 7.71; requires C, 71.62;
H, 7.76%.
FeCl2-mediated degradation of 10-(2-phenylallyl)deoxo-
artemisinin (11a)
To a solution of 11a (0.14 g, 0.4 mmol) in CH3CN (13 mL) was
added FeCl24H2O (0.1 g, 0.5 mmol) under nitrogen atmos-
phere. The reaction was left stirring at rt for 30 min before being
ﬁltered through Celite and washed with CH3CN. Concentration
under reduced pressure and ﬂash column chromatography
using ethyl acetate and hexane (1 : 10) as eluent yielded the
product 12 as yellow oil (0.86 g, 60% yield). νmax (Nujol mull)/
cm1 3042.1, 2926.3, 1713.8, 1628.8; 1H NMR (300 MHz,
CDCl3) δ 7.99 (1H, s, HCO), 7.43–7.21 (5H, m, Ar), 5.35 (1H,
br s, CCH), 5.14 (2H, m, CCH & 10-H), 2.96–1.26 (12H, m),
2.11 (3H, s, CH3), 1.01 (3H, d, J = 6.3 Hz), 0.99 (3H, d, J =
6.9 Hz, CH3); 
13C NMR (75 MHz, CDCl3) δ 213.31, 209.02,
160.66, 144.16, 140.12, 128.47, 127.79, 126.33, 115.85, 72.53,
57.52, 54.42, 41.38, 38.22, 34.60, 34.13, 31.02, 29.81, 20.40,
20.36, 12.26; MS m/z (CI, NH3) 355.3 (13%), 339.3 (100),
221.1 (6); Found 402.26497. C24H36NO4 [M  NH4]
 requires
402.26443.
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